IndraLab

Statements

USP8 activates TGF-β/SMAD. 3 / 3
| 3
reach
"USP8 activates the TGF-β/SMAD signaling pathway, which can EMT, tumor cell diffusion, and metastasis."
39979972
reach
"Pharmacological inhibition of USP8 antagonizes TGF-β/SMAD signaling, and reduces TβRII stability and the number of TβRII+ crEVs to prevent CD8+ T cell exhaustion and to reactivate anti-tumor immunity."
35811497
reach
"Inhibiting USP8 impairs TGF-β/SMAD signal transduction, leading to reduced stability of the β receptor II (βRII) and a decreased quantity of TβRII + circulating extracellular vesicles (crEVs), which in turn diminishes CD8 + T-cell exhaustion and reinstates anti-tumor responses [56]."
39979972